# Worked Example: Launching an FDA-Approved Synthetic-Biology Drug

**Setup.** Helix Therapeutics is a synthetic-biology company that has just received FDA approval for **Veridine** (a first-in-class engineered enzyme-replacement therapy for a rare metabolic disorder). Helix is not a thousand-person pharma. Its standing human core is eleven people: a **Chief Medical Officer** (the licensed physician who owns clinical and safety judgment), a **VP Regulatory Affairs** (the responsible person on FDA correspondence), a **VP Commercial / Market Access**, a **Qualified Person / VP Quality** accountable for GMP batch release, a General Counsel, a CFO, and a handful of scientists and operators. Everything between approval and a patient's first infusion — and the continuous obligations after — is run by an **orchestrator agent** that decomposes the launch into specialized agentic skills, hires them from agent marketplaces, contracts onchain, settles in stablecoins, and exposes a real-time audit trail. The humans don't do less *accountable* work; they do almost none of the *assembly* work, and they sign the things only a licensed human may sign.

## The Walkthrough

**1. Post-approval kickoff.** The CMO and VP Regulatory set the launch objective in the orchestrator's console: commercial availability in the U.S. within 16 weeks, three EU markets to follow, with hard guardrails — no promotional claim ships without medical/legal/regulatory (MLR) sign-off; no batch ships without the Qualified Person's release; all spend under a programmable treasury policy. The orchestrator stands up the pipelines (regulatory, CMC/manufacturing, supply chain, market access, commercial, pharmacovigilance) and initializes shared context: the approved label, the CMC dossier, the REMS requirements, the treasury policy.

**2. Hiring the regulatory & labeling agent.** The orchestrator queries an **agent marketplace** for a *regulatory-affairs & labeling* specialist. Candidates carry machine-readable metadata and **verifiable credentials**: who built the agent, a Circle **KYB** attestation that the operator is a real, in-good-standing entity, a track record of accepted FDA submissions, and — critically here — an attestation that its outputs are governed by a named, licensed regulatory professional. The orchestrator shortlists two, checks reputation rooted in KYC, and engages **RegLabel.ai** on an onchain contract: draft the carton/insert artwork-text package and the launch-readiness regulatory checklist for **$28,000**, with escrowed USDC released on two milestones. A **proving oracle** confirms the structured-product-label submission was accepted into the FDA gateway; but the contract also has a **mandatory human-judgment gate** — the VP Regulatory must e-sign before submission. Agent prepares; human signs; oracle proves acceptance; escrow releases.

**3. CMC / manufacturing coordination and a just-in-time credit draw.** Veridine is made by a contract manufacturer (CMO) in Ireland; fill-finish is in Switzerland. A **CMC-coordination agent** (hired at **$0.04 per coordination event**, metered as nanopayments) manages tech-transfer documents, batch records, and the release-testing schedule across the CMO, a QC-testing CRO in Germany, and Helix's quality system. Demand modeling says first-year volume needs a manufacturing scale-up that costs **$6.2M** up front but is paid back over the first two commercial quarters. Rather than dilute or wait on a bank, the treasury agent draws **just-in-time onchain credit**: a $4M USDC facility against contracted distributor purchase orders as collateral, priced and funded in hours. Paying the Irish CMO (EUR) and the German CRO (EUR) from a USDC treasury happens through invisible **atomic FX** (StableFX) — the agents quote in euros, settle in USDC, and the FX leg clears inside the same transaction. **None of this releases drug.** The Qualified Person still signs each batch release after reviewing the batch record and CoA; that signature is the oracle that unlocks the downstream shipping contracts.

**4. Supply chain & cold-chain logistics.** A **cold-chain logistics agent** is engaged to orchestrate 2–8°C distribution from the Swiss fill-finish site to U.S. specialty distributors. Pricing is consumption-based — **$120 per shipment lane configured + $0.002 per IoT telemetry reading ingested**. The smart contract releases payment only when a **delivery/cold-chain telemetry oracle** confirms the shipment stayed in range end-to-end; an excursion automatically quarantines the lot and notifies the Quality human rather than paying out. This is where physical reality bites: agents can book, route, and verify in minutes, but the product still moves at the speed of validated cold-chain freight.

**5. Market access — recursive sub-hiring.** The VP Commercial hires a **market-access & payer agent**, MAxis, on a hybrid contract: **$45,000 base + 0.5% of adjudicated first-year covered lives**. MAxis cannot itself be expert in every U.S. payer. So it **recursively sub-hires** region-specific agents from the marketplace — a **Medicare/Part-B reimbursement agent**, a **commercial-payer formulary agent**, and a **Medicaid best-price/340B agent** — each on its own agent-to-agent onchain contract (roughly **$6,000–$12,000** each, escrowed). MAxis decomposes the work, the sub-agents produce coding/J-code dossiers and payer value narratives, MAxis recomposes them into a national access plan, and settlement cascades automatically: when MAxis's milestone is verified, its wallet pays the sub-agents from the same onchain flow. Accountability traces cleanly: sub-agent → its wallet/credentials → its KYC'd creator, all the way up. The pricing recommendation, however, lands on a **human gate** — list price and gross-to-net are a fiduciary and legal decision the CFO and General Counsel sign, not the agent.

**6. Medical-affairs and HCP-facing content.** A **medical-affairs content agent** drafts HCP education, MOA explainers, and field-rep enablement; an **HCP-targeting agent** segments prescribers using licensed claims data. Every externally-facing asset routes through an automated **MLR-prep agent** and then a **mandatory MLR sign-off gate** — the medical, legal, and regulatory humans approve before anything is published or a rep can use it. Agents draft at machine speed; the compliance review remains a deliberate human act, and the onchain log records exactly which human approved which version when.

**7. Pharmacovigilance stand-up.** Before launch, a **pharmacovigilance / adverse-event monitoring agent** is engaged on a standing subscription-plus-consumption contract (**$15,000/month + per-case processing fees**). It ingests intake channels, triages signals, and drafts safety reports — but expedited reporting decisions and any signal that could change the benefit-risk profile escalate to the CMO, whose medical judgment and signature are non-delegable.

**8. Launch and early post-market.** With label finalized (human-signed), batches released (Qualified Person-signed), access plan approved (CFO/GC-signed), and PV live, Veridine goes commercially available. In the first 90 days, the orchestrator runs the machine continuously: reconciling distributor pull-through, metering field activity, paying sub-agents and vendors in USDC across borders, drawing and repaying the credit facility against incoming receivables — while every regulated decision stays gated to a named human.

## Where the Humans Sit

**In the loop (mandatory, accountable sign-off):** VP Regulatory on FDA submissions and labeling; Qualified Person/VP Quality on every GMP batch release; CMO on safety/medical judgment, expedited AE reporting, and benefit-risk; the MLR trio on all promotional and HCP content; CFO and General Counsel on pricing, gross-to-net, and contracts. These are licensed/fiduciary acts the framework deliberately keeps non-delegable.

**On the loop (objectives and oversight):** The CMO and VP Commercial set goals, guardrails, and treasury policy, then supervise dashboards and exception alerts rather than assembling work. The orchestrator escalates only at the defined gates and on anomalies (a cold-chain excursion, a safety signal, an out-of-policy spend).

## What Runs Onchain

- **Identity & credentials:** every agent's KYB/KYC attestation, professional-licensure linkage, and verifiable credentials live onchain via Circle's **Agent Stack / Agent Wallets**.
- **Contracts:** org-to-agent and agent-to-agent arrangements are smart contracts with work specs, acceptance criteria, escrow, event-based release, proving oracles, and explicit human sign-off gates.
- **Payments & settlement:** USDC settlement, atomic FX (StableFX) for EUR-denominated CMO/CRO payments, **x402** for agent invocation, nanopayments for metered coordination, **CPN + tokenized cards** to reach legacy vendor banking rails, sub-second finality with USDC gas and policy enforcement on **Arc**.
- **Real-time auditability (the point for this domain):** instead of an ex-post document dump during an FDA inspection, the regulator and Helix's risk officers get a **live, canonical, provable ledger** — which agent did what, under which credential, approved by which licensed human, paid how much, verified by which oracle. Governance moving between humans and machines is itself auditable in real time.

## The Agents Hired

| Agent (role) | How discovered | Pricing model | Settlement | Verified / who signs |
|---|---|---|---|---|
| Regulatory & labeling (RegLabel.ai) | Marketplace, KYB + licensure VC | $28,000, 2 milestones | USDC escrow | FDA-acceptance oracle; **VP Regulatory signs** |
| CMC / manufacturing coordination | Marketplace, track record VC | $0.04/event (nanopayments) | USDC metered | Batch-record review; **Qualified Person signs release** |
| Cold-chain logistics | Marketplace, logistics credentials | $120/lane + $0.002/telemetry reading | USDC, x402 | Cold-chain telemetry oracle; Quality reviews excursions |
| Market access & payer (MAxis) | Marketplace, KYB | $45k + 0.5% covered lives | USDC escrow | Recomposed plan; **CFO/GC sign pricing** |
| ↳ Medicare / commercial / Medicaid sub-agents | Sub-hired by MAxis (A2A) | $6k–$12k each | USDC cascade | Verified by MAxis, traced to each KYC'd creator |
| Medical-affairs content + HCP targeting | Marketplace, licensed-data VC | Consumption | USDC, x402 | **MLR human sign-off gate** |
| Pharmacovigilance / AE monitoring | Marketplace, safety credentials | $15k/mo + per-case | USDC subscription+consumption | **CMO signs** expedited reports / benefit-risk |

## What's Still Human, Regulated, Slow, or Physical

The economic OS makes discovery, contracting, payment, and verification nearly instantaneous — but the binding constraints don't vanish, and pretending otherwise would be dishonest. **FDA post-market obligations** (REMS, post-approval commitments, annual reports) run on the agency's clock and the CMO's judgment. **GMP manufacturing and batch release** are gated by physical production, release testing, and a Qualified Person's signature — agents can coordinate the paperwork, not certify the chemistry. **Cold-chain logistics** moves real vials through real freight at validated temperatures; an excursion is a physical event, not a ledger entry. **Pharmacovigilance** can be triaged by agents but is owned, medically, by a licensed physician. And **professional accountability** — regulatory, medical, quality, legal, fiduciary — remains attached to named, licensed humans whose signatures the smart contracts treat as required oracles. The transformation is real: a lean human core orchestrates a launch that once took a large organization, with continuous auditability regulators could only dream of. But the machine runs *up to* the regulated gates and stops, every time, for a human to decide and sign.